Doxifluridine

Doxifluridine
Clinical data
Other names	Doxyfluridine; doxifluridine; 5'-deoxy-5-fluorouridine; 5'-deoxy-5'-fluorouridine; 5'-fluoro-5'-deoxyuridine; 5'-dFUrd; 5'-DFUR; Furtulon; Ro 21-9738
Identifiers
	IUPAC name 1-[(2R,3R,4S,5R)-3,4-Dihydroxy-5-methyloxolan-2-yl]-5-fluoropyrimidine-2,4-dione;
CAS Number	3094-09-5 ;
PubChem CID	18343;
ChemSpider	17322;
UNII	V1JK16Y2JP;
CompTox Dashboard (EPA)	DTXSID2022967 ;
ECHA InfoCard	100.019.491
Chemical and physical data
Formula	C9H11FN2O5
Molar mass	246.194 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C(=O)NC2=O)F)O)O;
	InChI InChI=1S/C9H11FN2O5/c1-3-5(13)6(14)8(17-3)12-2-4(10)7(15)11-9(12)16/h2-3,5-6,8,13-14H,1H3,(H,11,15,16)/t3-,5-,6-,8-/m1/s1; Key:ZWAOHEXOSAUJHY-ZIYNGMLESA-N;

Doxifluridine is a second generation nucleoside analog prodrug developed by Roche and used as a cytostatic agent in chemotherapy in several Asian countries including China and South Korea. Doxifluridine is not FDA-approved for use in the USA. It is currently being evaluated in several clinical trials as a stand-alone or combination therapy treatment.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.